

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 April 2025 (17.04.2025)



(10) International Publication Number
WO 2025/080661 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) C07D 487/04 (2006.01)
A61K 31/4155 (2006.01) A61P 17/14 (2006.01)
C07B 59/00 (2006.01) A61P 25/22 (2006.01)
C07D 231/10 (2006.01) A61P 25/24 (2006.01)

(21) International Application Number:

PCT/US2024/050499

(22) International Filing Date:

09 October 2024 (09.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/543,470	10 October 2023 (10.10.2023)	US
63/543,885	12 October 2023 (12.10.2023)	US
63/625,125	25 January 2024 (25.01.2024)	US
63/673,600	19 July 2024 (19.07.2024)	US
63/675,577	25 July 2024 (25.07.2024)	US
63/697,634	23 September 2024 (23.09.2024)	US


(71) Applicant: **SUN PHARMACEUTICAL INDUSTRIES, INC.** [US/US]; 2 Independence Way, Princeton, New Jersey 08540 (US).

(72) Inventors: **BRUMMEL, Christopher L.**; c/o Sun Pharmaceutical Industries, Inc., 65 Hayden Ave # 3000N, Lexington, Massachusetts 02421 (US). **CASELLA, James V.**; c/o Sun Pharmaceutical Industries, Inc., 65 Hayden Ave # 3000N, Lexington, Massachusetts 02421 (US). **HOLDEN, Meghan A.**; c/o Sun Pharmaceutical Industries, Inc., 65 Hayden Ave # 3000N, Lexington, Massachusetts 02421 (US).

(74) Agent: **WOODHOUSE, Scott M.**; Medler Ferro Woodhouse & Mills PLLC, 8201 Greensboro Dr, Suite 1060, McLean, Virginia 22102 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: METHOD OF TREATING HAIR LOSS DISORDERS



BID = twice daily; SALT = Severity of Alopecia Tool

NOTE: Percentages were based on observed data. *P* values were based on the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo. Missing values were imputed using MI under MAR assumptions.

[1] Responders are subjects with SALT score ≤ 20 .

**** *P* value ≤ 0.0001

(57) Abstract: The disclosure relates to treatment of Alopecia Areata comprising the administration of Compound (I) or a pharmaceutically acceptable salt thereof.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))